190 related articles for article (PubMed ID: 33651375)
1. Activation of soluble guanylyl cyclase signalling with cinaciguat improves impaired kidney function in diabetic mice.
Harloff M; Prüschenk S; Seifert R; Schlossmann J
Br J Pharmacol; 2022 Jun; 179(11):2460-2475. PubMed ID: 33651375
[TBL] [Abstract][Full Text] [Related]
2. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
Stehle D; Xu MZ; Schomber T; Hahn MG; Schweda F; Feil S; Kraehling JR; Eitner F; Patzak A; Sandner P; Feil R; Bénardeau A
Br J Pharmacol; 2022 Jun; 179(11):2476-2489. PubMed ID: 34096053
[TBL] [Abstract][Full Text] [Related]
3. Targeted Delivery of Soluble Guanylate Cyclase (sGC) Activator Cinaciguat to Renal Mesangial Cells via Virus-Mimetic Nanoparticles Potentiates Anti-Fibrotic Effects by cGMP-Mediated Suppression of the TGF-β Pathway.
Fleischmann D; Harloff M; Maslanka Figueroa S; Schlossmann J; Goepferich A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806499
[TBL] [Abstract][Full Text] [Related]
4. Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.
Hoffmann LS; Kretschmer A; Lawrenz B; Hocher B; Stasch JP
PLoS One; 2015; 10(12):e0145048. PubMed ID: 26717150
[TBL] [Abstract][Full Text] [Related]
5. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus.
Mátyás C; Németh BT; Oláh A; Hidi L; Birtalan E; Kellermayer D; Ruppert M; Korkmaz-Icöz S; Kökény G; Horváth EM; Szabó G; Merkely B; Radovits T
Cardiovasc Diabetol; 2015 Oct; 14():145. PubMed ID: 26520063
[TBL] [Abstract][Full Text] [Related]
6. Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
Chester M; Seedorf G; Tourneux P; Gien J; Tseng N; Grover T; Wright J; Stasch JP; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2011 Nov; 301(5):L755-64. PubMed ID: 21856817
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of soluble guanylyl cyclase in living cells proceeds without loss of haem and involves heterodimer dissociation as a common step.
Dai Y; Stuehr DJ
Br J Pharmacol; 2022 Jun; 179(11):2505-2518. PubMed ID: 33975383
[TBL] [Abstract][Full Text] [Related]
8. Cinaciguat ameliorates glomerular damage by reducing ERK1/2 activity and TGF-ß expression in type-1 diabetic rats.
Czirok S; Fang L; Radovits T; Szabó G; Szénási G; Rosivall L; Merkely B; Kökény G
Sci Rep; 2017 Sep; 7(1):11218. PubMed ID: 28894114
[TBL] [Abstract][Full Text] [Related]
9. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
10. Cinaciguat in combination with insulin induces a favorable effect on implant osseointegration in type 2 diabetic rats.
Jia T; Wang YN; Zhang J; Hao X; Zhang D; Xu X
Biomed Pharmacother; 2019 Oct; 118():109216. PubMed ID: 31319371
[TBL] [Abstract][Full Text] [Related]
11. The role of cGMP signalling in auditory processing in health and disease.
Marchetta P; Rüttiger L; Hobbs AJ; Singer W; Knipper M
Br J Pharmacol; 2022 Jun; 179(11):2378-2393. PubMed ID: 33768519
[TBL] [Abstract][Full Text] [Related]
12. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.
Salloum FN; Das A; Samidurai A; Hoke NN; Chau VQ; Ockaili RA; Stasch JP; Kukreja RC
Am J Physiol Heart Circ Physiol; 2012 Mar; 302(6):H1347-54. PubMed ID: 22268103
[TBL] [Abstract][Full Text] [Related]
13. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus.
Chester M; Tourneux P; Seedorf G; Grover TR; Gien J; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2009 Aug; 297(2):L318-25. PubMed ID: 19465519
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling.
Rüdebusch J; Benkner A; Nath N; Fleuch L; Kaderali L; Grube K; Klingel K; Eckstein G; Meitinger T; Fielitz J; Felix SB
Br J Pharmacol; 2022 Jun; 179(11):2430-2442. PubMed ID: 33247945
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide- and heme-independent activation of soluble guanylate cyclase attenuates peroxynitrite-induced endothelial dysfunction in rat aorta.
Korkmaz S; Loganathan S; Mikles B; Radovits T; Barnucz E; Hirschberg K; Li S; Hegedüs P; Páli S; Weymann A; Karck M; Szabó G
J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):70-7. PubMed ID: 22914857
[TBL] [Abstract][Full Text] [Related]
16. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
17. Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by the Protoporphyrin IX Mimetic Cinaciguat.
Kollau A; Opelt M; Wölkart G; Gorren ACF; Russwurm M; Koesling D; Mayer B; Schrammel A
Mol Pharmacol; 2018 Feb; 93(2):73-78. PubMed ID: 29138269
[TBL] [Abstract][Full Text] [Related]
18. Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.
Zabbarova IV; Ikeda Y; Kozlowski MG; Tyagi P; Birder LA; Chakrabarty B; Perera SK; Dhir R; Straub AC; Sandner P; Andersson KE; Drake MJ; Fry CH; Kanai AJ
J Pathol; 2022 Apr; 256(4):442-454. PubMed ID: 34936088
[TBL] [Abstract][Full Text] [Related]
19. Effects of soluble guanylate cyclase activation on heart transplantation in a rat model.
Loganathan S; Korkmaz-Icöz S; Radovits T; Li S; Mikles B; Barnucz E; Hirschberg K; Karck M; Szabó G
J Heart Lung Transplant; 2015 Oct; 34(10):1346-53. PubMed ID: 26210750
[TBL] [Abstract][Full Text] [Related]
20. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.
Ott IM; Alter ML; von Websky K; Kretschmer A; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Stasch JP; Hocher B
PLoS One; 2012; 7(8):e42623. PubMed ID: 22900035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
